Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting problem with the lungs that leads to many symptoms, poor quality of life, and greater use of the health care system. The aim of this study was to evaluate longitudinal changes in symptom distress among patients with chronic obstructive pulmonary disease (COPD) over a 6- months follow-up period and to examine the association between baseline symptom distress and disease severity. In total, 341 patients with COPD were recruited from the Department of Pulmonology at Maharishi Markandeshwar (Deemed to be University) Hospital in Mullana, Haryana, India. The Symptom Distress Scale (SDS) was used to calculate symptom distress at baseline, 3 months, and 6 months post-enrolment into the study. Demographics (age and sex) and clinical data (exacerbation history, number of medications take, etc.) were collected using a standardized data collection sheet and statistical analyses were done using SPSS version 25.0. Most of the patients were in GOLD Stage II (58.7%) or GOLD Stage III (28.4%). The mean SDS scores decreased substantially from a baseline score of 26.38 ± 8.18 to a score of 24.59 ± 8.18 at 3 months and a score of 21.65 ± 9.39 at 6 months (p < 0.001). There were strong correlations between baseline SDS scores and the SDS scores at 3 months (r = 0.951, p < 0.001) and at 6 months (r = 0.812, p < 0.001). Baseline SDS scores did not differ significantly between the COPD severity stages (p = 0.271). Multiple regression analysis revealed that age, gender, smoking status, COPD duration, and disease severity were not significant predictors of baseline symptom distress. A significant reduction in mean symptom distress scores was observed among patients with COPD over the 6-months follow-up period; however, the observation design does not allow conclusions regarding the factors responsible for these changes.
Omveer Singh, Adarsh, M. Mishra et al.· Respiratory Medicine· 0 citations
Ufasomes-vesicular systems formed from long-chain unsaturated fatty acids such as oleic acid-have re-emerged as cost-effective, biocompatible alternatives to phospholipid liposomes. These bilayered assemblies self-organize at specific pH conditions and efficiently encapsulate both hydrophilic and lipophilic drugs. Their highly fluid membranes, attributed to cis-double-bond-induced structural disorder, enhance interaction with biological barriers, particularly the stratum corneum, making them valuable for topical and transdermal delivery.This review outlines the chemistry and self-assembly of ufasomes, followed by a critical appraisal of preparation techniques-including thin-film hydration and reverse-phase evaporation-and their influence on vesicle size, stability, and encapsulation efficiency. Advantages such as biocompatibility, biodegradability, and pH-responsive release are highlighted alongside limitations including pH-dependent instability and oxidative susceptibility. Key characterization approaches are summarized, and the therapeutic scope of ufasomes is examined, encompassing enhanced dermal delivery of antifungals and antidepressants, targeted cancer therapy, and improved oral bioavailability of nutraceuticals like oleuropein. The review concludes with emerging strategies to overcome current constraints and perspectives on advancing ufasomes toward clinical translation as versatile drug-delivery systems.
Raghavi Bansal, D. Baloni, M. Mishra· Pharmaceutical development a...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.